

Beyond efficacy and safety, what else influences prescription decisions for neurodegenerative diseases?

Our research focus

There is a wide range of medication available for the treatment and management of neurodegenerative diseases and choosing the drug that is best for your patient can be challenging. At Aston University* we would like to give you the opportunity to participate in, and contribute to, evidence-based, practitioner-driven research that aims to optimise treatment choice for patients with neurodegenerative diseases. Our research will focus on identifying factors that influence decisions made by healthcare professionals (HCPs) to prescribe or not prescribe certain medications for neurodegenerative diseases.

Prescribing clinician? Take part in our research

- Are you based in Europe?
- Have you prescribed medication for a neurodegenerative disease in the past 2 years?

Your views and experiences are important to making change happen. If you recognise a need to change prescribing practices and see improvements to optimising treatment choice, then please consider taking part in our short online survey: <https://tinyurl.com/AstonPrescribingSurvey>

For more study information, please email **Dr Emma Begley** on e.begley@aston.ac.uk



What is involved?

Only 25 minutes of your time to click the link and complete the anonymous survey.

We will ask you to consider whether you agree or disagree with several statements regarding factors that may influence your prescription decisions. For example, if you often consider prescribing something new or different to what you usually do.

What do you gain?

- An opportunity to win our charity prize draw, where we will make a donation to a neurodegenerative disease charity of your choice (first prize = £/€100; two second prizes of £/€50 each)
- A summary of our research findings, highlighting practice informed insight about prescribing across Europe, for neurodegenerative diseases

Study outcomes

- Increased knowledge about prescribing practices for neurodegenerative diseases
- Identify what needs to change to improve the reach of medication
- Develop information and communications that clinicians can relate to
- Potentially inform clinical training modules to improve prescribing practices
- Enable medication to reach patients faster and more effectively

REC ID: [HLS21064], [v4], [18.08.2023]

*Knowledge Transfer Partnerships (KTPs) aim to help businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills that reside within the UK knowledge base

This KTP project was co-funded by UKRI through Innovate UK and Alphamaxim Limited